Kazumasa Kamei
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kazumasa Kamei has a total of 74 co-authors. Here are the top co-authors by number of shared publications:
- Naohiro Yonemoto
Department of Biostatistics, Faculty of Medicine, University of Toyama, Toyama, Japan
4 shared publications - Akira Yuasa
Japan Access & Value, Pfizer Japan Inc., Tokyo, Japan
3 shared publications - Kanae Togo
Pfizer Japan Inc., Tokyo, Japan
3 shared publications Akira Yuasa
Japan Access and Value, Pfizer Japan Inc., Tokyo, Japan
2 shared publicationsCamille Moyon
Health Economics and Outcomes Research
2 shared publicationsCatriona Crossan
Health Economics and Outcomes Research
2 shared publications
Latest Publications
- Open Access
- 19 October 2026
- Published by Wiley in The Journal of Dermatology
Response to “Psychological Distress in Vitiligo Requires an Action‐Linked Pathway Beyond HADS Classification”
- 19 October 2026
- Published by Wiley in The Journal of Dermatology
Open AccessResponse to “Psychological Distress in Vitiligo Requires an Action‐Linked Pathway Beyond HADS Classification”
- Open Access
- 8 September 2026
- Published by Springer Nature in Advances in Therapy
- p. 1-20
Comparative Cost-Effectiveness of Advanced Treatment Sequences for Moderately to Severely Active Ulcerative Colitis in Japan
Introduction Ulcerative colitis (UC) is a chronic immune-mediated inflammatory disease characterized by a relapsing course, substantial symptom burden, and long-term healthcare utilization. Although multiple advanced therapies (ATs) are available for patients with moderately to severely active UC, evidence to guide optimal treatment sequencing remains limited, particularly in Japan. This study evaluated the cost-effectiveness of clinically relevant AT sequences for moderately to severely active UC in Japan. Methods A hybrid decision-tree and Markov model was developed to compare AT sequences over a lifetime horizon from the payer perspective. The model captured both induction and maintenance phases for each therapy. Efficacy and safety inputs were derived from a previously published Bayesian network meta-analysis and supplemented with Japan-specific clinical and economic data. Costs and quality-adjusted life years (QALYs) were discounted at an annual rate of 2.0%. Incremental cost-effectiveness ratios (ICERs) were calculated, and cost-effectiveness was assessed against a Japanese cost-effectiveness threshold of JPY 7,500,000 per QALY (USD 49,547 per QALY). Results A total of 79 treatment sequences were evaluated. First-line etrasimod followed by second-line upadacitinib yielded the greatest health benefit (17.801 QALYs). Four treatment sequences—infliximab followed by ustekinumab, infliximab followed by etrasimod, infliximab followed by upadacitinib, and etrasimod followed by upadacitinib—were located on the efficiency frontier. Compared with infliximab–ustekinumab, infliximab–etrasimod resulted in an ICER of JPY 1,095,181 (USD 7235) per QALY. In turn, infliximab–upadacitinib had an ICER of JPY 1,218,896 (USD 8052) per QALY compared with infliximab–etrasimod. Etrasimod–upadacitinib had an ICER of JPY 6,684,442 (USD 44,160) per QALY compared with infliximab–upadacitinib. All ICERs were below the Japanese cost-effectiveness threshold. Conclusion Under the assumptions of this model, a treatment sequence with first-line etrasimod followed by second-line upadacitinib was identified as the most cost-effective strategy for advanced therapy-naïve patients with moderately to severely active UC in Japan.
- 8 September 2026
- Published by Springer Nature in Advances in Therapy
- p. 1-20
Open AccessComparative Cost-Effectiveness of Advanced Treatment Sequences for Moderately to Severely Active Ulcerative Colitis in Japan
Introduction Ulcerative colitis (UC) is a chronic immune-mediated inflammatory disease characterized by a relapsing course, substantial symptom burden, and long-term healthcare utilization. Although multiple advanced therapies (ATs) are available for patients with moderately to severely active UC, evidence to guide optimal treatment sequencing remains limited, particularly in Japan. This study evaluated the cost-effectiveness of clinically relevant AT sequences for moderately to severely active UC in Japan. Methods A hybrid decision-tree and Markov model was developed to compare AT sequences over a lifetime horizon from the payer perspective. The model captured both induction and maintenance phases for each therapy. Efficacy and safety inputs were derived from a previously published Bayesian network meta-analysis and supplemented with Japan-specific clinical and economic data. Costs and quality-adjusted life years (QALYs) were discounted at an annual rate of 2.0%. Incremental cost-effectiveness ratios (ICERs) were calculated, and cost-effectiveness was assessed against a Japanese cost-effectiveness threshold of JPY 7,500,000 per QALY (USD 49,547 per QALY). Results A total of 79 treatment sequences were evaluated. First-line etrasimod followed by second-line upadacitinib yielded the greatest health benefit (17.801 QALYs). Four treatment sequences—infliximab followed by ustekinumab, infliximab followed by etrasimod, infliximab followed by upadacitinib, and etrasimod followed by upadacitinib—were located on the efficiency frontier. Compared with infliximab–ustekinumab, infliximab–etrasimod resulted in an ICER of JPY 1,095,181 (USD 7235) per QALY. In turn, infliximab–upadacitinib had an ICER of JPY 1,218,896 (USD 8052) per QALY compared with infliximab–etrasimod. Etrasimod–upadacitinib had an ICER of JPY 6,684,442 (USD 44,160) per QALY compared with infliximab–upadacitinib. All ICERs were below the Japanese cost-effectiveness threshold. Conclusion Under the assumptions of this model, a treatment sequence with first-line etrasimod followed by second-line upadacitinib was identified as the most cost-effective strategy for advanced therapy-naïve patients with moderately to severely active UC in Japan.
- Open Access
- 9 March 2026
- Published by Wiley in The Journal of Dermatology
- Vol. 53 (4) , 619-631
Cost‐Effectiveness Analysis of Ritlecitinib Compared With No Treatment in Patients With Severe Alopecia Areata in Japan
The efficacy and safety of ritlecitinib, a dual inhibitor of Janus kinase 3 (JAK3) and tyrosine kinase expressed in hepatocellular carcinoma (TEC) family kinases, have been demonstrated in the ALLEGRO phase 2b/3 trial that enrolled patients aged ≥ 12 years with alopecia areata (AA) and ≥ 50% scalp hair loss. The present analysis evaluated the cost‐effectiveness of ritlecitinib compared with no treatment for patients with AA and ≥ 50% scalp hair loss in Japan from a societal perspective. A Markov model stratified by health states based on the Severity of Alopecia Tool (SALT) was developed to estimate the lifetime costs, including productivity loss, and quality‐adjusted life years (QALYs) associated with the treatment of AA. The comparator was no treatment, and clinical parameters were based on the ALLEGRO phase 2b/3 trial. Costs and QALYs were discounted at an annual rate of 2%, and the incremental cost‐effectiveness ratio (ICER) was calculated. Over a lifetime horizon and with the base‐case societal perspective, the incremental QALYs and incremental costs of ritlecitinib 50 mg were 1.09 QALYs and 5 262 471 Japanese yen (JPY) (34 766 United States dollars [USD]), respectively. The ICER was 4 816 589 JPY (31 820 USD) per QALY, which was below the cost‐effectiveness threshold in Japan of 5 000 000 JPY (33 032 USD) per QALY. A one‐way sensitivity analysis showed that parameters with the most notable effect on the ICER were the utility for patients with SALT score ≥ 50, percentage of work time missed due to presenteeism for patients with SALT score ≥ 50, and the discontinuation rate of ritlecitinib 50 mg. These results indicate that ritlecitinib 50 mg is cost‐effective compared with no treatment for patients with AA and hair loss on ≥ 50% of the scalp from a societal perspective in Japan.
- 9 March 2026
- Published by Wiley in The Journal of Dermatology
- Vol. 53 (4) , 619-631
Open AccessCost‐Effectiveness Analysis of Ritlecitinib Compared With No Treatment in Patients With Severe Alopecia Areata in Japan
The efficacy and safety of ritlecitinib, a dual inhibitor of Janus kinase 3 (JAK3) and tyrosine kinase expressed in hepatocellular carcinoma (TEC) family kinases, have been demonstrated in the ALLEGRO phase 2b/3 trial that enrolled patients aged ≥ 12 years with alopecia areata (AA) and ≥ 50% scalp hair loss. The present analysis evaluated the cost‐effectiveness of ritlecitinib compared with no treatment for patients with AA and ≥ 50% scalp hair loss in Japan from a societal perspective. A Markov model stratified by health states based on the Severity of Alopecia Tool (SALT) was developed to estimate the lifetime costs, including productivity loss, and quality‐adjusted life years (QALYs) associated with the treatment of AA. The comparator was no treatment, and clinical parameters were based on the ALLEGRO phase 2b/3 trial. Costs and QALYs were discounted at an annual rate of 2%, and the incremental cost‐effectiveness ratio (ICER) was calculated. Over a lifetime horizon and with the base‐case societal perspective, the incremental QALYs and incremental costs of ritlecitinib 50 mg were 1.09 QALYs and 5 262 471 Japanese yen (JPY) (34 766 United States dollars [USD]), respectively. The ICER was 4 816 589 JPY (31 820 USD) per QALY, which was below the cost‐effectiveness threshold in Japan of 5 000 000 JPY (33 032 USD) per QALY. A one‐way sensitivity analysis showed that parameters with the most notable effect on the ICER were the utility for patients with SALT score ≥ 50, percentage of work time missed due to presenteeism for patients with SALT score ≥ 50, and the discontinuation rate of ritlecitinib 50 mg. These results indicate that ritlecitinib 50 mg is cost‐effective compared with no treatment for patients with AA and hair loss on ≥ 50% of the scalp from a societal perspective in Japan.
- Open Access
- 27 November 2025
- Published by Wiley in The Journal of Dermatology
- Vol. 53 (2) , 200-209
Health‐Related Quality of Life and Psychological Burden of Patients With Vitiligo in Japan
Vitiligo is a disorder characterized by depigmentation of the skin and is known to impact patients' health‐related quality of life (HRQoL). In Japan, HRQoL studies on vitiligo remain limited in size and scope, and factors contributing to impaired HRQoL, as well as the psychological burden, have not been adequately evaluated. This study aimed to assess HRQoL and symptoms of anxiety and depression in patients with vitiligo in Japan. A web‐based survey was completed by 271 patients with vitiligo aged 18 to 79 years. The survey included the 12‐item Short Form Health Survey version 2 (SF‐12v2) and the Dermatology Life Quality Index (DLQI) to assess HRQoL, as well as the Hospital Anxiety and Depression Scale (HADS). The role/social component summary score (mean ± standard deviation) of the SF‐12v2 in vitiligo patients was 45.8 ± 14.5, which was lower than the Japanese population norm (national standard values for Japanese). Based on the DLQI, which is specific to dermatologic diseases, 62.7% of patients reported at least a small effect on their daily lives. HADS anxiety and depression scores showed that 38.0% and 40.3% of patients, respectively, were classified as doubtful or definite cases. Subgroup analyses revealed that higher DLQI and HADS scores were associated with sex, age, disease duration, affected body surface area (BSA), and history of relapse. Notably, nonlinear associations in these measures were observed for disease duration and affected BSA, with the highest scores seen in patients with an intermediate range of disease duration and affected BSA. These findings underscore the need for timely and sustained treatment strategies to control symptoms, reduce psychological distress, and prevent relapse, which may help not only improve clinical outcomes but also maintain long‐term HRQoL in individuals with vitiligo.
- 27 November 2025
- Published by Wiley in The Journal of Dermatology
- Vol. 53 (2) , 200-209
Open AccessHealth‐Related Quality of Life and Psychological Burden of Patients With Vitiligo in Japan
Vitiligo is a disorder characterized by depigmentation of the skin and is known to impact patients' health‐related quality of life (HRQoL). In Japan, HRQoL studies on vitiligo remain limited in size and scope, and factors contributing to impaired HRQoL, as well as the psychological burden, have not been adequately evaluated. This study aimed to assess HRQoL and symptoms of anxiety and depression in patients with vitiligo in Japan. A web‐based survey was completed by 271 patients with vitiligo aged 18 to 79 years. The survey included the 12‐item Short Form Health Survey version 2 (SF‐12v2) and the Dermatology Life Quality Index (DLQI) to assess HRQoL, as well as the Hospital Anxiety and Depression Scale (HADS). The role/social component summary score (mean ± standard deviation) of the SF‐12v2 in vitiligo patients was 45.8 ± 14.5, which was lower than the Japanese population norm (national standard values for Japanese). Based on the DLQI, which is specific to dermatologic diseases, 62.7% of patients reported at least a small effect on their daily lives. HADS anxiety and depression scores showed that 38.0% and 40.3% of patients, respectively, were classified as doubtful or definite cases. Subgroup analyses revealed that higher DLQI and HADS scores were associated with sex, age, disease duration, affected body surface area (BSA), and history of relapse. Notably, nonlinear associations in these measures were observed for disease duration and affected BSA, with the highest scores seen in patients with an intermediate range of disease duration and affected BSA. These findings underscore the need for timely and sustained treatment strategies to control symptoms, reduce psychological distress, and prevent relapse, which may help not only improve clinical outcomes but also maintain long‐term HRQoL in individuals with vitiligo.
- Open Access
- 28 July 2025
- Published by Taylor & Francis in Expert Review of Pharmacoeconomics & Outcomes Research
- Vol. 25 (9) , 1309-1322
Health and economic impact of 20-valent pneumococcal conjugate vaccine for adults aged 66–84 years in Japan and Shiga prefecture
The Japanese National Immunization Program against pneumococcal disease (PD) includes 23-valent pneumococcal polysaccharide vaccine (PPSV23) but does not provide vaccination for adults aged ≥66 years. We evaluated the cost-effectiveness of 20-valent pneumococcal conjugate vaccine (PCV20) in adults aged 66-84 years with no history of PPSV23 vaccination in Japan and assessed the potential economic and health impact of introducing PCV20 on the local government (specifically, Shiga prefecture). Using a Markov model, we assessed lifetime costs, quality-adjusted life-years (QALYs), and number of prevented cases and deaths caused by PD. In national-level analysis, PCV20 was cost-effective compared with no vaccination under incremental cost-effectiveness ratio threshold of Japanese yen (JPY) 5,000,000/QALY, i.e. JPY1,677,401/QALY and JPY1,351,811/QALY from payer and societal perspectives, respectively. PCV20 was dominant (less costly and more effective) compared with PPSV23. In local-level analysis, the introduction of PCV20 required initial costs but resulted in greater cost savings related to medical expenses (-JPY424 and -JPY430 per person) and nursing care (-JPY560 and -JPY575 per person) compared to PPSV23 and no vaccination, respectively. PCV20 is cost-effective compared with PPSV23 and no vaccination in adults aged 66-84 years, which could reduce the future healthcare burden in Japan.
- 28 July 2025
- Published by Taylor & Francis in Expert Review of Pharmacoeconomics & Outcomes Research
- Vol. 25 (9) , 1309-1322
Open AccessHealth and economic impact of 20-valent pneumococcal conjugate vaccine for adults aged 66–84 years in Japan and Shiga prefecture
The Japanese National Immunization Program against pneumococcal disease (PD) includes 23-valent pneumococcal polysaccharide vaccine (PPSV23) but does not provide vaccination for adults aged ≥66 years. We evaluated the cost-effectiveness of 20-valent pneumococcal conjugate vaccine (PCV20) in adults aged 66-84 years with no history of PPSV23 vaccination in Japan and assessed the potential economic and health impact of introducing PCV20 on the local government (specifically, Shiga prefecture). Using a Markov model, we assessed lifetime costs, quality-adjusted life-years (QALYs), and number of prevented cases and deaths caused by PD. In national-level analysis, PCV20 was cost-effective compared with no vaccination under incremental cost-effectiveness ratio threshold of Japanese yen (JPY) 5,000,000/QALY, i.e. JPY1,677,401/QALY and JPY1,351,811/QALY from payer and societal perspectives, respectively. PCV20 was dominant (less costly and more effective) compared with PPSV23. In local-level analysis, the introduction of PCV20 required initial costs but resulted in greater cost savings related to medical expenses (-JPY424 and -JPY430 per person) and nursing care (-JPY560 and -JPY575 per person) compared to PPSV23 and no vaccination, respectively. PCV20 is cost-effective compared with PPSV23 and no vaccination in adults aged 66-84 years, which could reduce the future healthcare burden in Japan.
- Open Access
- 6 July 2025
- Published by Springer Nature in Infectious Diseases and Therapy
- Vol. 14 (8) , 1755-1773
Cost-Effectiveness Analysis of a Bivalent RSVPreF Vaccine in Japanese Adults Aged 60 Years and Older
Introduction Respiratory syncytial virus (RSV) is a major cause of acute respiratory illness. A bivalent RSV prefusion F protein-based (RSVpreF) vaccine was approved in Japan to prevent RSV-related diseases in older adults in 2024. This study evaluated the cost-effectiveness of the RSVpreF vaccine compared with no vaccination in Japanese adults aged 60 years and older from the payer and societal perspectives. Methods A population-based, multi-cohort, Markov-type model was used to estimate the economic and health impact of vaccination against RSV over a lifetime horizon. Model inputs were derived from published Japanese and international sources. Vaccine effectiveness was derived from clinical trial data and assumed to wane over time. The base-case analysis was conducted assuming a vaccination rate of 50%. Scenario analyses, along with deterministic and probabilistic sensitivity analyses, were conducted to assess the uncertainty around model inputs. Results The RSVpreF vaccine was anticipated to reduce 204,145 cases of RSV hospitalization, 113,170 cases of RSV emergency department visits, 542,790 cases of RSV outpatient visits, and 27,764 RSV-related deaths versus no vaccination. These reductions in disease burden resulted in savings of Japanese yen (JPY) 176,121 million in medical expenses and JPY 161,307 million in productivity losses. There was an incremental gain of 290,312 quality-adjusted life-years (QALYs), with incremental cost-effectiveness ratios (ICERs) of JPY 1,458,898/QALY from the payer perspective and JPY 903,263/QALY from the societal perspective, which was below the cost-effectiveness threshold of JPY 5 million/QALY. The scenario and sensitivity analyses confirmed the robustness of the results. Conclusions The RSVpreF vaccine is cost-effective compared to no vaccination for adults aged 60 years and older in Japan. It has the potential to provide significant public health benefits by reducing the burden of RSV-related diseases.
- 6 July 2025
- Published by Springer Nature in Infectious Diseases and Therapy
- Vol. 14 (8) , 1755-1773
Open AccessCost-Effectiveness Analysis of a Bivalent RSVPreF Vaccine in Japanese Adults Aged 60 Years and Older
Introduction Respiratory syncytial virus (RSV) is a major cause of acute respiratory illness. A bivalent RSV prefusion F protein-based (RSVpreF) vaccine was approved in Japan to prevent RSV-related diseases in older adults in 2024. This study evaluated the cost-effectiveness of the RSVpreF vaccine compared with no vaccination in Japanese adults aged 60 years and older from the payer and societal perspectives. Methods A population-based, multi-cohort, Markov-type model was used to estimate the economic and health impact of vaccination against RSV over a lifetime horizon. Model inputs were derived from published Japanese and international sources. Vaccine effectiveness was derived from clinical trial data and assumed to wane over time. The base-case analysis was conducted assuming a vaccination rate of 50%. Scenario analyses, along with deterministic and probabilistic sensitivity analyses, were conducted to assess the uncertainty around model inputs. Results The RSVpreF vaccine was anticipated to reduce 204,145 cases of RSV hospitalization, 113,170 cases of RSV emergency department visits, 542,790 cases of RSV outpatient visits, and 27,764 RSV-related deaths versus no vaccination. These reductions in disease burden resulted in savings of Japanese yen (JPY) 176,121 million in medical expenses and JPY 161,307 million in productivity losses. There was an incremental gain of 290,312 quality-adjusted life-years (QALYs), with incremental cost-effectiveness ratios (ICERs) of JPY 1,458,898/QALY from the payer perspective and JPY 903,263/QALY from the societal perspective, which was below the cost-effectiveness threshold of JPY 5 million/QALY. The scenario and sensitivity analyses confirmed the robustness of the results. Conclusions The RSVpreF vaccine is cost-effective compared to no vaccination for adults aged 60 years and older in Japan. It has the potential to provide significant public health benefits by reducing the burden of RSV-related diseases.
- Open Access
- 27 June 2025
- Published by Wiley in The Journal of Dermatology
- Vol. 52 (8) , 1255-1262
Perceived Stigma and Mental Health Disorders Among Adults With Alopecia Areata Living in Japan
Alopecia areata (AA) is a common disorder that causes hair loss and can significantly impact quality of life, which may be partially due to AA‐related stigma. Examining the impact of AA on psychosocial health is important for understanding the burden experienced by patients with AA. The primary objective of this study was to examine mental health and sleep conditions, hair growth satisfaction, and AA‐related stigma perceptions among individuals diagnosed with AA in Japan. The study used patients' self‐reported data collected from the National Health and Wellness Survey conducted in Japan in 2023. Collected data included demographic characteristics and comorbidities; among those with a self‐reported clinical diagnosis of AA, additional information on clinical characteristics, treatments, and perceived AA‐related stigma was captured. Results were analyzed and stratified by self‐assessed disease severity. Among the full sample (30 013 adults living in Japan), 471 respondents reported a clinical diagnosis of AA, including 347 mild cases, 100 moderate cases, and 24 severe cases. A diagnosed mental health disorder in the past year was reported by 57 respondents (12.1%), and 67 (14.2%) reported a diagnosed sleep condition in the past year. Less than half of respondents (47.4%) were satisfied with their current hair growth, and satisfaction decreased with increasing disease severity. Overall, 70.3% of respondents reported feelings of embarrassment, 55.0% felt that others judged them negatively, and 50.3% felt that others treated them negatively due to AA. A higher proportion of respondents with a severe case (54.2%) reported feeling embarrassed to have AA “very much so” compared with respondents who had mild (15.3%) or moderate (26.0%) cases. Perceived AA‐associated stigma increased with disease severity. Overall, this study demonstrated the prevalence of AA‐related disease stigma and mental health conditions among individuals with AA living in Japan, underscoring the importance of mental health support for patients with AA.
- 27 June 2025
- Published by Wiley in The Journal of Dermatology
- Vol. 52 (8) , 1255-1262
Open AccessPerceived Stigma and Mental Health Disorders Among Adults With Alopecia Areata Living in Japan
Alopecia areata (AA) is a common disorder that causes hair loss and can significantly impact quality of life, which may be partially due to AA‐related stigma. Examining the impact of AA on psychosocial health is important for understanding the burden experienced by patients with AA. The primary objective of this study was to examine mental health and sleep conditions, hair growth satisfaction, and AA‐related stigma perceptions among individuals diagnosed with AA in Japan. The study used patients' self‐reported data collected from the National Health and Wellness Survey conducted in Japan in 2023. Collected data included demographic characteristics and comorbidities; among those with a self‐reported clinical diagnosis of AA, additional information on clinical characteristics, treatments, and perceived AA‐related stigma was captured. Results were analyzed and stratified by self‐assessed disease severity. Among the full sample (30 013 adults living in Japan), 471 respondents reported a clinical diagnosis of AA, including 347 mild cases, 100 moderate cases, and 24 severe cases. A diagnosed mental health disorder in the past year was reported by 57 respondents (12.1%), and 67 (14.2%) reported a diagnosed sleep condition in the past year. Less than half of respondents (47.4%) were satisfied with their current hair growth, and satisfaction decreased with increasing disease severity. Overall, 70.3% of respondents reported feelings of embarrassment, 55.0% felt that others judged them negatively, and 50.3% felt that others treated them negatively due to AA. A higher proportion of respondents with a severe case (54.2%) reported feeling embarrassed to have AA “very much so” compared with respondents who had mild (15.3%) or moderate (26.0%) cases. Perceived AA‐associated stigma increased with disease severity. Overall, this study demonstrated the prevalence of AA‐related disease stigma and mental health conditions among individuals with AA living in Japan, underscoring the importance of mental health support for patients with AA.
- Open Access
- 5 June 2024
- Published by Springer Nature in Infectious Diseases and Therapy
- Vol. 13 (7) , 1665-1682
Cost-Effectiveness Analysis of Maternal Respiratory Syncytial Virus Vaccine in Protecting Infants from RSV Infection in Japan
Introduction Respiratory syncytial virus (RSV) is one of the major causes of respiratory tract infections among children. Until recently, the monoclonal antibody palivizumab was the only RSV prophylaxis available in Japan. In 2024, the bivalent RSV prefusion F protein-based (RSVpreF) vaccine was approved for the prevention of RSV infection in infants by active immunization of pregnant women. In this study, we assessed the cost-effectiveness of a combined strategy of RSVpreF vaccine and palivizumab in Japanese setting. Methods Using a Markov model, we evaluated prevented cases and deaths of medically attended RSV infections from birth to age 11 months for each of the three healthcare settings: inpatient (hospitalization), emergency department visits, and outpatient visits. Incremental cost-effectiveness ratios (ICERs) were calculated from economic outcomes (intervention costs, medication costs, and productivity losses) and quality-adjusted life years (QALYs). Further, we calculated the maximum price of RSVpreF vaccine within which the program would be cost-effective. Results In comparison with the current prophylaxis (palivizumab alone), a combined prophylaxis of year-round RSVpreF vaccination of pregnant women and palivizumab prescription for premature infants born in < 32 weeks gestational age (wGA) and all infants with high risk prevented 14,382 medically attended cases of RSV (hospitalization, 7490 cases; emergency department, 2239 cases; outpatient, 4653 cases) and 7 deaths, respectively. From a healthcare payer perspective, when the price of RSVpreF vaccine was equal to or less than ¥23,948 (US $182), a combination prophylaxis was cost-effective under the ICER threshold of ¥5 million per QALY. The other combination prophylaxis of year-round RSVpreF vaccination and palivizumab prescription of premature born in < 32 wGA regardless of risk in infants was a dominant strategy (more effective and less costly). Conclusion A combined prophylaxis of year-round RSVpreF vaccine and palivizumab could be a cost-effective strategy to protect neonates throughout the infant stage (< 1 years old) in Japan.
- 5 June 2024
- Published by Springer Nature in Infectious Diseases and Therapy
- Vol. 13 (7) , 1665-1682
Open AccessCost-Effectiveness Analysis of Maternal Respiratory Syncytial Virus Vaccine in Protecting Infants from RSV Infection in Japan
Introduction Respiratory syncytial virus (RSV) is one of the major causes of respiratory tract infections among children. Until recently, the monoclonal antibody palivizumab was the only RSV prophylaxis available in Japan. In 2024, the bivalent RSV prefusion F protein-based (RSVpreF) vaccine was approved for the prevention of RSV infection in infants by active immunization of pregnant women. In this study, we assessed the cost-effectiveness of a combined strategy of RSVpreF vaccine and palivizumab in Japanese setting. Methods Using a Markov model, we evaluated prevented cases and deaths of medically attended RSV infections from birth to age 11 months for each of the three healthcare settings: inpatient (hospitalization), emergency department visits, and outpatient visits. Incremental cost-effectiveness ratios (ICERs) were calculated from economic outcomes (intervention costs, medication costs, and productivity losses) and quality-adjusted life years (QALYs). Further, we calculated the maximum price of RSVpreF vaccine within which the program would be cost-effective. Results In comparison with the current prophylaxis (palivizumab alone), a combined prophylaxis of year-round RSVpreF vaccination of pregnant women and palivizumab prescription for premature infants born in < 32 weeks gestational age (wGA) and all infants with high risk prevented 14,382 medically attended cases of RSV (hospitalization, 7490 cases; emergency department, 2239 cases; outpatient, 4653 cases) and 7 deaths, respectively. From a healthcare payer perspective, when the price of RSVpreF vaccine was equal to or less than ¥23,948 (US $182), a combination prophylaxis was cost-effective under the ICER threshold of ¥5 million per QALY. The other combination prophylaxis of year-round RSVpreF vaccination and palivizumab prescription of premature born in < 32 wGA regardless of risk in infants was a dominant strategy (more effective and less costly). Conclusion A combined prophylaxis of year-round RSVpreF vaccine and palivizumab could be a cost-effective strategy to protect neonates throughout the infant stage (< 1 years old) in Japan.
- Open Access
- 9 May 2024
- Published by Taylor & Francis in Expert Review of Vaccines
- Vol. 23 (1) , 546-560
Cost-effectiveness analysis of adult pneumococcal conjugate vaccines for pneumococcal disease in Japan
The 23-valent pneumococcal polysaccharide vaccine (PPSV23) is used in the Japanese National Immunization Program for older adults and adults with increased risk for pneumococcal disease, however, disease incidence and associated burden remain high. We evaluated the cost-effectiveness of pneumococcal conjugate vaccines (PCVs) for adults aged 65 years and high-risk adults aged 60-64 years in Japan. Using a Markov model, we evaluated lifetime costs using societal and healthcare payer perspectives and estimated quality-adjusted life-years (QALYs), and number of prevented cases and deaths caused by invasive pneumococcal disease (IPD) and non-IPD. The base case analysis used a societal perspective. In comparison with PPSV23, the 20-valent PCV (PCV20) prevented 127 IPD cases 10,813 non-IPD cases (inpatients: 2,461, outpatients: 8,352) and 226 deaths, and gained more QALYs (+0.0015 per person) with less cost (-JPY22,513 per person). All sensitivity and scenario analyses including a payer perspective analysis indicated that the incremental cost-effectiveness ratios (ICERs) were below the cost-effectiveness threshold value in Japan (JPY5 million/QALY). PCV20 is both cost saving and more effective than PPSV23 for adults aged 65 years and high-risk adults aged 60-64 years in Japan.
- 9 May 2024
- Published by Taylor & Francis in Expert Review of Vaccines
- Vol. 23 (1) , 546-560
Open AccessCost-effectiveness analysis of adult pneumococcal conjugate vaccines for pneumococcal disease in Japan
The 23-valent pneumococcal polysaccharide vaccine (PPSV23) is used in the Japanese National Immunization Program for older adults and adults with increased risk for pneumococcal disease, however, disease incidence and associated burden remain high. We evaluated the cost-effectiveness of pneumococcal conjugate vaccines (PCVs) for adults aged 65 years and high-risk adults aged 60-64 years in Japan. Using a Markov model, we evaluated lifetime costs using societal and healthcare payer perspectives and estimated quality-adjusted life-years (QALYs), and number of prevented cases and deaths caused by invasive pneumococcal disease (IPD) and non-IPD. The base case analysis used a societal perspective. In comparison with PPSV23, the 20-valent PCV (PCV20) prevented 127 IPD cases 10,813 non-IPD cases (inpatients: 2,461, outpatients: 8,352) and 226 deaths, and gained more QALYs (+0.0015 per person) with less cost (-JPY22,513 per person). All sensitivity and scenario analyses including a payer perspective analysis indicated that the incremental cost-effectiveness ratios (ICERs) were below the cost-effectiveness threshold value in Japan (JPY5 million/QALY). PCV20 is both cost saving and more effective than PPSV23 for adults aged 65 years and high-risk adults aged 60-64 years in Japan.
- Open Access
- 2 May 2024
- Published by Taylor & Francis in Expert Review of Vaccines
- Vol. 23 (1) , 485-497
Cost-effectiveness analysis of 20-valent pneumococcal conjugate vaccine for routine pediatric vaccination programs in Japan
The Japanese National Immunization Program currently includes the pediatric 13valent pneumococcal conjugate vaccine (PCV13) to prevent pneumococcal infections. We aimed to evaluate the cost-effectiveness of 20-valent PCV (PCV20) as a pediatric vaccine versus PCV13. A decision-analytic Markov model was used to estimate expected costs, qualityadjusted life-years (QALYs), and prevented cases and deaths caused by invasive pneumococcal disease, pneumonia, and acute otitis media over a ten-year time horizon from the societal and healthcare payer perspectives. PCV20 (price: 8,102 Japanese yen [JPY]) was dominant, i.e. less costly and more effective, over PCV13 (gained 294,599 QALYs and reduced JPY 352.6 billion [2.6 billion United States dollars, USD] from the societal perspective and JPY 178.9 billion [USD 1.4 billion] from the payer perspective). Sensitivity and scenario analyses validated the robustness of the base scenario results. When comparing PCV20 with PCV13, the threshold analysis revealed an incremental cost-effectiveness ratio that was within the threshold value (JPY 5 million/QALY) at a maximum acquisition price of JPY 74,033 [USD 563] (societal perspective) and JPY 67,758 [USD 515] (payer perspective). As a pediatric vaccine, PCV20 was dominant over PCV13 regardless of the study perspective.
- 2 May 2024
- Published by Taylor & Francis in Expert Review of Vaccines
- Vol. 23 (1) , 485-497
Open AccessCost-effectiveness analysis of 20-valent pneumococcal conjugate vaccine for routine pediatric vaccination programs in Japan
The Japanese National Immunization Program currently includes the pediatric 13valent pneumococcal conjugate vaccine (PCV13) to prevent pneumococcal infections. We aimed to evaluate the cost-effectiveness of 20-valent PCV (PCV20) as a pediatric vaccine versus PCV13. A decision-analytic Markov model was used to estimate expected costs, qualityadjusted life-years (QALYs), and prevented cases and deaths caused by invasive pneumococcal disease, pneumonia, and acute otitis media over a ten-year time horizon from the societal and healthcare payer perspectives. PCV20 (price: 8,102 Japanese yen [JPY]) was dominant, i.e. less costly and more effective, over PCV13 (gained 294,599 QALYs and reduced JPY 352.6 billion [2.6 billion United States dollars, USD] from the societal perspective and JPY 178.9 billion [USD 1.4 billion] from the payer perspective). Sensitivity and scenario analyses validated the robustness of the base scenario results. When comparing PCV20 with PCV13, the threshold analysis revealed an incremental cost-effectiveness ratio that was within the threshold value (JPY 5 million/QALY) at a maximum acquisition price of JPY 74,033 [USD 563] (societal perspective) and JPY 67,758 [USD 515] (payer perspective). As a pediatric vaccine, PCV20 was dominant over PCV13 regardless of the study perspective.